KNSA vs. C

Last updated Jun 4, 2026

KNSA (Kiniksa Pharmaceuticals, Ltd.) and C (Citigroup Inc.) are both stocks. KNSA operates in Biotechnology (Healthcare), while C operates in Banks - Diversified (Financial Services). Over the past 5 years, KNSA returned 29.11%/yr vs 14.21%/yr for C. At a 0.18 correlation, their price movements are largely independent.

Performance

KNSA vs. C - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in Kiniksa Pharmaceuticals, Ltd. (KNSA) and Citigroup Inc. (C). The values are adjusted to include any dividend payments, if applicable.

Returns By Period

In the year-to-date period, KNSA achieves a 16.00% return, which is significantly higher than C's 12.46% return.

KNSA

• 1D: 1.98%
• 1M: -16.96%
• YTD: 16.00%
• 6M: 17.89%
• 1Y: 64.38%
• 3Y*: 48.51%
• 5Y*: 29.11%
• 10Y*: —

C

• 1D: -1.01%
• 1M: 3.42%
• YTD: 12.46%
• 6M: 22.96%
• 1Y: 73.63%
• 3Y*: 45.73%
• 5Y*: 14.21%
• 10Y*: 14.47%

*Multi-year figures are annualized to reflect compound growth (CAGR)

KNSA vs. C - Yearly Performance Comparison

	2026 (YTD)	2025	2024	2023	2022	2021	2020	2019	2018
KNSA Kiniksa Pharmaceuticals, Ltd.	16.00%	108.54%	12.77%	17.09%	27.27%	-33.39%	59.76%	-60.63%	44.27%
C Citigroup Inc.	12.46%	70.38%	41.93%	18.98%	-22.09%	0.93%	-19.70%	57.82%	-23.89%

Correlation

The correlation between KNSA and C is 0.06, meaning there is essentially no relationship between their price movements. Each responds to its own set of market drivers, making them strong candidates for combining in a diversified portfolio.

	Correlation
Correlation (1Y) Calculated over the trailing 1-year period	0.06
Correlation (3Y) Calculated over the trailing 3-year period	0.20
Correlation (5Y) Calculated over the trailing 5-year period	0.20
Correlation (All Time) Calculated using the full available price history since May 25, 2018	0.18

The correlation between KNSA and C shifts across timeframes, from 0.06 (1 year) to 0.20 (5 years), reflecting how their relationship changes across market environments.

Fundamentals

Market Cap KNSA : $3.94B C : $230.76B
EPS KNSA : $0.92 C : $8.65
PE Ratio KNSA : 51.96 C : 15.02
PS Ratio KNSA : 5.03 C : 1.40
PB Ratio KNSA : 6.51 C : 1.21
Total Revenue (TTM) KNSA : $754.05M C : $171.19B
Gross Profit (TTM) KNSA : $294.06M C : $77.85B
EBITDA (TTM) KNSA : $101.06M C : $24.12B

Return for Risk

KNSA vs. C — Risk / Return Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

KNSA

KNSA Risk / Return Rank: 83
KNSA Sharpe Ratio Rank: 81
KNSA Sortino Ratio Rank: 81
KNSA Omega Ratio Rank: 79
KNSA Calmar Ratio Rank: 83
KNSA Martin Ratio Rank: 89

C

C Risk / Return Rank: 91
C Sharpe Ratio Rank: 92
C Sortino Ratio Rank: 90
C Omega Ratio Rank: 89
C Calmar Ratio Rank: 91
C Martin Ratio Rank: 92

The rank (0–100) shows how this investment's returns compare to the risk taken. Higher = better. Based on the past 12 months of data, combining Sharpe, Sortino, and other metrics used by quantitative funds and institutional investors.

KNSA vs. C - Risk-Adjusted Trends Comparison

This table presents a comparison of risk-adjusted performance metrics for Kiniksa Pharmaceuticals, Ltd. (KNSA) and Citigroup Inc. (C). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

	KNSA	C	Difference
Sharpe ratio Return per unit of total volatility	1.48	2.66	-1.17
Sortino ratio Return per unit of downside risk	2.38	3.30	-0.92
Omega ratio Gain probability vs. loss probability	1.30	1.42	-0.13
Calmar ratio Return relative to maximum drawdown	3.06	5.01	-1.95
Martin ratio Return relative to average drawdown	11.39	14.45	-3.05
Data is calculated on a 1-year rolling basis and updated daily. The trend shows the change in the indicator over the past month.

KNSA vs. C - Sharpe Ratio Comparison

The current KNSA Sharpe Ratio is 1.48, which is lower than the C Sharpe Ratio of 2.66. The chart below compares the historical Sharpe Ratios of KNSA and C, calculated using daily returns over the previous 12 months. A higher Sharpe Ratio indicates better risk-adjusted performance relative to the risk-free rate.

Sharpe Ratios by Period

	KNSA	C	Difference
Sharpe Ratio (1Y) Calculated over the trailing 1-year period	1.48	2.66	-1.17
Sharpe Ratio (5Y) Calculated over the trailing 5-year period	0.55	0.49	+0.06
Sharpe Ratio (10Y) Calculated over the trailing 10-year period	—	0.44	—
Sharpe Ratio (All Time) Calculated using the full available price history	0.19	0.15	+0.03

Drawdowns

KNSA vs. C - Drawdown Comparison

The maximum KNSA drawdown since its inception was -83.06%, smaller than the maximum C drawdown of -98.00%. Use the drawdown chart below to compare losses from any high point for KNSA and C.

Drawdown Indicators

	KNSA	C	Difference
Max Drawdown Largest peak-to-trough decline	-83.06%	-98.00%	+14.94%
Max Drawdown (1Y) Largest decline over 1 year	-21.12%	-14.76%	-6.36%
Max Drawdown (3Y) Largest decline over 3 years	-34.14%	-31.31%	-2.83%
Max Drawdown (5Y) Largest decline over 5 years	-53.17%	-47.56%	-5.61%
Max Drawdown (10Y) Largest decline over 10 years	—	-56.51%	—
Current Drawdown Current decline from peak	-19.55%	-65.32%	+45.77%
Average Drawdown Average peak-to-trough decline	-40.26%	-43.50%	+3.24%
Ulcer Index Depth and duration of drawdowns from previous peaks	5.67%	5.11%	+0.56%

Volatility

KNSA vs. C - Volatility Comparison

Kiniksa Pharmaceuticals, Ltd. (KNSA) has a higher volatility of 10.38% compared to Citigroup Inc. (C) at 7.44%. This indicates that KNSA's price experiences larger fluctuations and is considered to be riskier than C based on this measure. The chart below showcases a comparison of their rolling one-month volatility.

Volatility by Period

	KNSA	C	Difference
Volatility (1M) Calculated over the trailing 1-month period	10.38%	7.44%	+2.94%
Volatility (6M) Calculated over the trailing 6-month period	33.56%	22.66%	+10.90%
Volatility (1Y) Calculated over the trailing 1-year period	43.77%	27.86%	+15.91%
Volatility (5Y) Calculated over the trailing 5-year period, annualized	53.49%	29.11%	+24.38%
Volatility (10Y) Calculated over the trailing 10-year period, annualized	63.66%	33.20%	+30.46%

Dividends

KNSA vs. C - Dividend Comparison

KNSA has not paid dividends to shareholders, while C's dividend yield for the trailing twelve months is around 1.85%.

Position	TTM	2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015
C Citigroup Inc.	1.85%	1.99%	3.10%	4.04%	4.51%	3.38%	3.31%	2.40%	2.96%	1.29%	0.71%	0.31%
KNSA Kiniksa Pharmaceuticals, Ltd.	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%

Financials

KNSA vs. C - Profitability Comparison

The chart below illustrates the profitability comparison between Kiniksa Pharmaceuticals, Ltd. and Citigroup Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

KNSA - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a gross profit of 0.00 and revenue of 214.27M. Therefore, the gross margin over that period was 0.0%.

C - Gross Margin

Gross margin is calculated as gross profit divided by revenue. For the three months ending on Jun 2026, Citigroup Inc. reported a gross profit of 21.76B and revenue of 44.14B. Therefore, the gross margin over that period was 49.3%.

KNSA - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported an operating income of 29.27M and revenue of 214.27M, resulting in an operating margin of 13.7%.

C - Operating Margin

Operating margin is calculated as operating income divided by revenue. For the three months ending on Jun 2026, Citigroup Inc. reported an operating income of 7.52B and revenue of 44.14B, resulting in an operating margin of 17.0%.

KNSA - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Kiniksa Pharmaceuticals, Ltd. reported a net income of 22.59M and revenue of 214.27M, resulting in a net margin of 10.5%.

C - Net Margin

Net margin is calculated as net income divided by revenue. For the three months ending on Jun 2026, Citigroup Inc. reported a net income of 5.79B and revenue of 44.14B, resulting in a net margin of 13.1%.

Frequently Asked Questions

Can I hold both KNSA and C in my portfolio?

KNSA and C have a correlation of 0.06, meaning they provide meaningful diversification benefit when combined. Depending on your allocation goals, holding both could reduce overall portfolio risk.

Which is riskier, KNSA or C?

KNSA has higher volatility (10.38%) compared to C (7.44%). In terms of maximum drawdown, KNSA dropped -83.06% vs C's -98.00%.

Which has better risk-adjusted returns?

C currently has the higher Sharpe Ratio (2.66 vs 1.48), meaning it's delivered slightly more return per unit of risk over the trailing 12 months. However, this ranking shifts over time - use the Risk/Return Score above for a more comprehensive view that combines Sharpe, Sortino, and other measures used by quantitative funds.